Nivolumab Biosimilar (Mabxience Research)

N/A

Report date: 2025/10/30 20:00:05

Base Information

Drug NameNivolumab Biosimilar (Mabxience Research)
Drug Alias NameMB-11 (Mabxience Research)MB11 (Mabxience Research)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUkrainePortugal
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMabxience Research SL
China Registration ClassN/A

Develop Information

Active CompaniesMabxience Research SL
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A